 |
 |

Neurochemical Markers Do Not Correlate With Cognitive Decline in the Lewy Body Variant of Alzheimer Disease
Marwan N. Sabbagh, MD;
Jody Corey-Bloom, MD, PhD;
Pietro Tiraboschi, MD;
Ronald Thomas, PhD;
Eliezer Masliah, MD;
Leon J. Thal, MD
Arch Neurol. 1999;56:1458-1461.
Background Reductions in neocortical synapses and cholinergic function occur in patients with Alzheimer disease (AD) and in patients with the Lewy body variant of AD (LBV). The relation between these losses and cognitive decline has been reported frequently in patients with AD but remains unclear for patients with LBV.
Objectives To investigate the relation between clinical markers of disease progression and choline acetyltransferase activity or synaptic density, measured by synaptophysin (Syn) level, in patients with LBV, and to investigate the relation of these neurochemical markers with one another.
Methods Brain specimens of 41 patients with autopsy-confirmed (National Institute on Aging criteria for AD) LBV were examined. The last Mini-Mental State Examination and Blessed Information-Memory-Concentration test scores before death were reviewed. Midfrontal synapse counts were quantified by a dot-immunobinding assay for Syn. Choline acetyltransferase activity of the midfrontal cortex was assayed by established protocols.
Results The last Mini-Mental State Examination score before death did not correlate significantly with Syn level (n=25, r=0.25, P=.24); however, there was a trend toward significance for the relation between last Mini-Mental State Examination score and choline acetyltransferase activity (n=39, r=0.31, P=.05). The last Blessed Information-Memory-Concentration test score did not correlate with either Syn level (n=24, r=-0.17, P=.44) or choline acetyltransferase activity (n=39, r=-0.16, P=.33). Finally, there was only a modest correlation between Syn level and choline acetyltransferase activity (n=25 , r=0.38, P=.06), which did not reach statistical significance.
Conclusion Unlike AD, neurochemical markers do not appear to correlate well with cognitive decline in LBV.
From the Department of Neurosciences, University of California, San Diego, La Jolla (Drs Sabbagh, Corey-Bloom, Thomas, and Masliah); the Neurology Service, San Diego Veterans Affairs Medical Center, San Diego (Drs Sabbagh, Corey-Bloom, and Thal); and Neurologia Prima, Ospedali Riuniti di Bergamo, Bergamo, Italy (Dr Tiraboschi).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Dementia Associated With Lewy Bodies: Dilemmas and Directions
Myron F. Weiner
Arch Neurol. 1999;56(12):1441-1442.
EXTRACT
| FULL TEXT
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(12):1538-1539.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
ERK1/2 Activation Mediates Abeta Oligomer-induced Neurotoxicity via Caspase-3 Activation and Tau Cleavage in Rat Organotypic Hippocampal Slice Cultures
Chong et al.
J. Biol. Chem. 2006;281:20315-20325.
ABSTRACT
| FULL TEXT
{beta}-Amyloid-induced Dynamin 1 Depletion in Hippocampal Neurons: A POTENTIAL MECHANISM FOR EARLY COGNITIVE DECLINE IN ALZHEIMER DISEASE
Kelly et al.
J. Biol. Chem. 2005;280:31746-31753.
ABSTRACT
| FULL TEXT
Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease
Tiraboschi et al.
Arch Gen Psychiatry 2002;59:946-951.
ABSTRACT
| FULL TEXT
Dementia Associated With Lewy Bodies: Dilemmas and Directions
Weiner
Arch Neurol 1999;56:1441-1442.
FULL TEXT
|